HK1023516A1 - Pharmaceutical composition containing stimulators of interferon-gamma - Google Patents

Pharmaceutical composition containing stimulators of interferon-gamma

Info

Publication number
HK1023516A1
HK1023516A1 HK00102799A HK00102799A HK1023516A1 HK 1023516 A1 HK1023516 A1 HK 1023516A1 HK 00102799 A HK00102799 A HK 00102799A HK 00102799 A HK00102799 A HK 00102799A HK 1023516 A1 HK1023516 A1 HK 1023516A1
Authority
HK
Hong Kong
Prior art keywords
gamma
interferon
pharmaceutical composition
composition containing
stimulators
Prior art date
Application number
HK00102799A
Other languages
English (en)
Inventor
Mark William James Ferguson
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Publication of HK1023516A1 publication Critical patent/HK1023516A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
HK00102799A 1995-08-18 2000-05-10 Pharmaceutical composition containing stimulators of interferon-gamma HK1023516A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9516967A GB2304342A (en) 1995-08-18 1995-08-18 Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma

Publications (1)

Publication Number Publication Date
HK1023516A1 true HK1023516A1 (en) 2000-09-15

Family

ID=10779448

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00102799A HK1023516A1 (en) 1995-08-18 2000-05-10 Pharmaceutical composition containing stimulators of interferon-gamma

Country Status (13)

Country Link
EP (2) EP0972521B1 (fr)
JP (2) JP4070809B2 (fr)
AT (2) ATE208402T1 (fr)
AU (1) AU713809B2 (fr)
CA (1) CA2229590C (fr)
DE (2) DE69626050T2 (fr)
DK (2) DK0972521T3 (fr)
ES (2) ES2164911T3 (fr)
GB (1) GB2304342A (fr)
HK (1) HK1023516A1 (fr)
PT (2) PT845007E (fr)
WO (1) WO1997007136A2 (fr)
ZA (1) ZA966953B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1137766B1 (fr) 1998-12-09 2005-09-28 Protein Design Labs, Inc. Usage des anticorps il-12 pour le traitement du psoriasis humain
WO2000071148A2 (fr) * 1999-05-26 2000-11-30 The Brigham And Women's Hospital, Inc. Utilisations therapeutiques d'agents modulant l'activite de l'actine alpha de muscle lisse
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
WO2008099829A1 (fr) * 2007-02-14 2008-08-21 Japan Science And Technology Agency Procédé de formation d'adhésion intestinale chez un animal expérimental, procédé de production d'animal expérimental présentant une adhésion intestinale, procédé de criblage d'agent de prévention d'adhérence intestinale, et agent de p
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
RU2539383C1 (ru) * 2013-11-29 2015-01-20 Закрытое акционерное общество "ФИРН М" (ЗАО "ФИРН М") Фармацевтическая композиция для лечения трофических язв и длительно незаживающих ран различной этиологии в виде мази

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
EP0311616B1 (fr) * 1986-06-17 1991-09-25 Biogen, Inc. Combinaisons d'interferons gamma et d'agents anti-inflammatoires ou anti-pyretiques pour le traitement de maladies
NL8700927A (nl) * 1987-04-16 1988-11-16 Stichting Rega V Z W Anti-interferon-gamma-antilichamen; en hun therapeutische toepassing.
CA1335792C (fr) * 1987-08-18 1995-06-06 Chaim O. Jacob Methode et forme posologique utilisant un antagoniste de l'interferon gamma pour lutter contre les maladies auto-immunes associees au cmh
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
IL88378A (en) * 1988-11-14 2000-11-21 Yeda Res & Dev Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
DE68927671T2 (de) * 1988-12-19 1997-05-07 American Cyanamid Co Produkte zur Behandlung des Endotoxin -Schocks bei einem Säugetier
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
AU625866B2 (en) * 1989-04-19 1992-07-16 F. Hoffmann-La Roche Ag Soluble interferon-gamma receptors and methods for their production
IT1231727B (it) * 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
DE69115917T2 (de) * 1990-09-27 1996-05-23 Schering Corp Humane gammainterferonantagonisten
JPH05506673A (ja) * 1991-02-22 1993-09-30 アムジエン・インコーポレーテツド 迅速な創傷の治癒を促進するためのｇｍ―ｃｓｆ及びｇ―ｃｓｆの使用
NL9101290A (nl) * 1991-07-23 1993-02-16 Stichting Rega V Z W Recombinant dna-molecuul voor de expressie van een fv-fragment van een antilichaam.
DE4234380A1 (de) * 1992-10-06 1994-04-07 Schering Ag Verwendung von Dopaminagonisten zur Aktivierung des gamma-Interferon-Produktion
AU5669694A (en) * 1992-11-20 1994-06-22 Schering Corporation Antagonists of human gamma interferon
US6558661B1 (en) * 1992-12-29 2003-05-06 Genentech, Inc. Treatment of inflammatory bowel disease with IFN-γ inhibitors
JPH09506263A (ja) * 1993-12-09 1997-06-24 アゲット，ミヒェル ＩＦＮ−γレセプターβ−鎖およびその誘導体

Also Published As

Publication number Publication date
DK0972521T3 (da) 2003-05-05
GB2304342A (en) 1997-03-19
GB9516967D0 (en) 1995-10-18
ES2164911T3 (es) 2002-03-01
PT845007E (pt) 2002-03-28
DK0845007T3 (da) 2001-12-17
JP2007119497A (ja) 2007-05-17
ATE231728T1 (de) 2003-02-15
AU713809B2 (en) 1999-12-09
DE69616803D1 (de) 2001-12-13
DE69616803T2 (de) 2002-06-20
AU6707196A (en) 1997-03-12
EP0972521A1 (fr) 2000-01-19
ES2192018T3 (es) 2003-09-16
JP4616291B2 (ja) 2011-01-19
WO1997007136A3 (fr) 1997-08-21
EP0845007A2 (fr) 1998-06-03
DE69626050D1 (de) 2003-03-06
JPH11511160A (ja) 1999-09-28
ZA966953B (en) 1998-02-16
ATE208402T1 (de) 2001-11-15
EP0972521B1 (fr) 2003-01-29
CA2229590C (fr) 2010-10-12
EP0845007B1 (fr) 2001-11-07
DE69626050T2 (de) 2004-01-22
WO1997007136A2 (fr) 1997-02-27
JP4070809B2 (ja) 2008-04-02
CA2229590A1 (fr) 1997-02-27
PT972521E (pt) 2003-06-30

Similar Documents

Publication Publication Date Title
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
AP2001002187A0 (en) Piperidines as CCR5 modulators.
AU7449598A (en) Medicinal composition for prevention or treatment of hepatopathy
BG104315A (en) Prostaglandine agonists and their application for the treatment of osteal diseases
ZA948B (en) Endothelin converting enzyme inhibitors
AU8452991A (en) 1-aryl-3-pyridinyl-2-propene-1-ones
AU1430492A (en) Pharmaceutical composition for the treatment of gastritis
AU4133997A (en) Pharmaceutical composition for the treatment of syndrome x of reaven
AU2748788A (en) Mixed compositions for treating hypercholesterolemia
HK1023516A1 (en) Pharmaceutical composition containing stimulators of interferon-gamma
ZA966578B (en) Pharmaceutical composition.
ZA886097B (en) Pharmaceutical composition for the treatment of psoriasis
AU623805B2 (en) New use of anti-progestomimetic compounds
IL88207A0 (en) Imidazole compounds and pharmaceutical compositions for the treatment of osteoporosis
ZA947813B (en) Hydroxyl ions as unique therapeutic agents and compounds that modulate these ions compositions employing these agents therapeutic methods for using such agents and processes for preparing them
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
AU4609693A (en) An interferon-alpha/beta binding protein its preparation and pharmaceutical compositions containing it
AU1506692A (en) Pharmaceutical compositions
EP0316639A3 (en) Azelastin embonate, process for its preparation and pharmaceutical compositions containing azelastin embonate as the active ingredient
AU8452791A (en) 1-phenyl-3-aryl-2-propyne-1-ones
UA23873A (uk) Лікувально-профілактичний препарат (його варіанти)
IL116680A0 (en) Pharmaceutical composition for the treatment of depression
IL86116A0 (en) Pharmaceutical compositions for the treatment of malaria
IL119250A0 (en) Pharmaceutical composition for the treatment of syndrome X of reaven
IL119403A0 (en) Pharmaceutical composition for the treatment of syndrome X of reaven

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110809